APH vs SPRO · P/E 40, rev $23.09B vs P/E 9.6, rev $48.0M
Amphenol Corporation (APH) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
APH currently screens at market cap $170.77B and trailing P/E 39.9. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the APH and SPRO stock pages for the full models.
Not investment advice.